secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001213900-24-067778
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading
--------------------------------------------------------------------------------

- FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.
- Oncology subsidiary merged with TenX Keane; Citius Oncology (Nasdaq: CTOR) starts trading Aug 13, 2024.
- Mino-Lok Phase 3 trial met primary and secondary endpoints; cash $17.9M as of June 30, 2024, with runway through Dec 2024.
- Net loss $10.6M ($0.06/sh) for Q3 ended June 30, 2024, vs $8.5M ($0.06/sh) a year ago; R&D expenses $2.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/0001213900-24-067778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/ea0211123-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-067778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer